<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(Suppl )</volume><submitter>Rodriguez-Otero P</submitter><journal>HemaSphere</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9011718</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL</pubmed_title><pmcid>PMC9011718</pmcid><pubmed_authors>Rowe E</pubmed_authors><pubmed_authors>Munshi N</pubmed_authors><pubmed_authors>Shah N</pubmed_authors><pubmed_authors>Agarwal A</pubmed_authors><pubmed_authors>Finney O</pubmed_authors><pubmed_authors>Campbell T</pubmed_authors><pubmed_authors>Berdeja J</pubmed_authors><pubmed_authors>Martin N</pubmed_authors><pubmed_authors>San-Miguel J</pubmed_authors><pubmed_authors>Rodriguez-Otero P</pubmed_authors><pubmed_authors>Jagannath S</pubmed_authors></additional><is_claimable>false</is_claimable><name>P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL</name><description/><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2025-04-26T13:01:21.325Z</modification><creation>2025-04-06T14:07:14.303Z</creation></dates><accession>S-EPMC9011718</accession><cross_references/></HashMap>